Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target
1. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA;2. Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA;3. Histopathology Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA;4. Division of Gynecologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Abstract:
Highlights
•SRPK1 is overexpressed in endometrial cancer and associated with poor survival.
•SRPK1 promotes endometrial cancer cell growth under nutrient-deprived conditions.
•Activation of EGFR-IGF1R-AKT signaling promotes resistance to SRPK1 inhibitors.
•Co-targeting SRPK1 and EGFR-IGF1R synergize blocking endometrial cancer cell growth.